ASH 2025: Disc Medicine CEO John Quisel walks us through the RALLY-MF Phase 2 trial data of DISC-0974 in anemia of myelofibrosis

He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin.